138 related articles for article (PubMed ID: 36075370)
1. Discovery of pyrrolo[2,3-d]pyrimidine-based molecules as a Wee1 inhibitor template.
Chen C; Wang Y; Hu MQ; Li H; Chen X; Qiang G; Sun Y; Zhu Y; Li B
Bioorg Med Chem Lett; 2022 Nov; 75():128973. PubMed ID: 36075370
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
Lakkaniga NR; Gunaganti N; Zhang L; Belachew B; Frett B; Leung YK; Li HY
Eur J Med Chem; 2020 Nov; 206():112691. PubMed ID: 32823007
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
5. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
Matheson CJ; Casalvieri KA; Backos DS; Reigan P
ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
[TBL] [Abstract][Full Text] [Related]
6. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
9. Discovery of pyrido[4,3-d]pyrimidinone derivatives as novel Wee1 inhibitors.
Ye Q; Ma J; Wang P; Wang C; Sun M; Zhou Y; Li J; Liu T
Bioorg Med Chem; 2023 May; 87():117312. PubMed ID: 37167712
[TBL] [Abstract][Full Text] [Related]
10. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wee1-like protein kinase to treat cancer.
Stathis A; Oza A
Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
[TBL] [Abstract][Full Text] [Related]
13. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2018 May; 151():836-848. PubMed ID: 29684894
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
17. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
[TBL] [Abstract][Full Text] [Related]
19. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
20. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
